Ricolinostat (, ; developmental code names ACY-1215 and ACY-63) is a histone deacetylase (HDAC) inhibitor which is under development for the treatment of diabetic neuropathies, multiple myeloma, and lymphoma. It is taken orally.
Pharmacology
+ Enzyme (nM) HDAC1 58 HDAC2 48 HDAC3 51 HDAC4 7,000 HDAC5 5,000 HDAC6 4.7 HDAC7 1,400 HDAC8 100 HDAC9 >10,000 HDAC10 HDAC11 >10,000 Refs:
Ricolinostat has been reported to have 10- to 21-fold selectivity for HDAC6 over HDAC1, HDAC2, HDAC3, and HDAC8 and greater than 1,000-fold selectivity for HDAC6 over other HDACs. It has been referred to as the first selective HDAC6 inhibitor and as a first-in-class selective HDAC6 inhibitor. However, although described as a highly selective HDAC6 inhibitor, the drug's selectivity for HDAC6 appears to be controversial. Ricolinostat has been found to improve cognition and memory in rodent models of Alzheimer's disease. It has also been found to reverse cognitive impairment induced by cisplatin, also known as chemotherapy cognitive impairment, in rodents. The pharmacokinetics of ricolinostat have been studied in rodents.
Side effects
Side effects of ricolinostat have been reported to include diarrhea, nausea, fatigue, anemia, and hypercalcemia, among others.
History
Ricolinostat was first described in the scientific literature by 2012. It has been developed by Dana-Farber Cancer Institute, Harvard University, 3E-Regenacy Pharmaceuticals (BC Regenacy), Columbia University, and Regenacy Pharmaceuticals. As of February 2025, the drug is in phase 2 clinical trials for diabetic neuropathies and multiple myeloma and is in phase 1/2 trials for lymphoma. It is or was also under development for a variety of other uses, including breast cancer, Charcot-Marie-Tooth disease, chronic lymphocytic leukemia, fallopian tube cancer, malignant melanoma, ovarian cancer, peripheral nervous system diseases, and peritoneal cancer, but no recent development has been reported for these indications.
See also Histone deacetylase inhibitor
References